All About Gout: Arcalyst Meets Phase III Prophylaxis Endpoint - BioWorld Online

All About Gout: Arcalyst Meets Phase III Prophylaxis Endpoint BioWorld Online ... of immunosuppression, though Arcalyst's half-life of one week could bode well if the firm eventually seeks to expand its use in chronic gout treatment. ... ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 ...PR Newswire (press release) all 74 news articles »

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease - MarketWatch (press release)

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease MarketWatch (press release) Unlike many forms of chronic uveitis, Behcet's uveitis is characterized by recurrent acute attacks or exacerbations. Without immediate treatment, major ... and more »

New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... - PR-inside.com (press release)

New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... PR-inside.com (press release) ACZ885 significantly reduced rate of acute flares up to 75% vs. anti-inflammatory colchicine in gout patients starting uric acid lowering therapy (UALT)[1] ... Novartis ACZ885 prevented acute flares in gout patiends shows studyFrontier India - News, Analysis, Opinion all 8 news articles »

Cheap gout drug shows promise in kidney disease - Reuters

MedIndia

Cheap gout drug shows promise in kidney disease Reuters LONDON (Reuters) - A drug commonly used to treat gout may help patients with chronic kidney disease keep their condition in check and reduce the risk of ... Gout Drug May Ease Kidney Disease SymptomsAHN | All Headline News Gout Drug Slows Kidney DiseaseMedPage Today Gout drug beneficial for kidney disease patientsSify Medscape all 37 news articles »